WO2006084412A1 - Verfahren zur reinigung von noroxymorphon-verbindungen - Google Patents
Verfahren zur reinigung von noroxymorphon-verbindungen Download PDFInfo
- Publication number
- WO2006084412A1 WO2006084412A1 PCT/CH2006/000087 CH2006000087W WO2006084412A1 WO 2006084412 A1 WO2006084412 A1 WO 2006084412A1 CH 2006000087 W CH2006000087 W CH 2006000087W WO 2006084412 A1 WO2006084412 A1 WO 2006084412A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- noroxymorphone
- hydrogenation
- hydrogen
- naltrexone
- Prior art date
Links
- VFVZOWSSOFEXPC-CXTNYUCXSA-N CN1C(CC23c4c5O[C@H]2C(C=C2)=O)(Cc4ccc5O)C1C32O Chemical compound CN1C(CC23c4c5O[C@H]2C(C=C2)=O)(Cc4ccc5O)C1C32O VFVZOWSSOFEXPC-CXTNYUCXSA-N 0.000 description 1
- QEYYTDYNANSOII-GWOJJWRWSA-N OC(C1C(C2)(Cc3ccc4O)C1CC1CC1)(C21c3c4O[C@H]11)C=CC1=O Chemical compound OC(C1C(C2)(Cc3ccc4O)C1CC1CC1)(C21c3c4O[C@H]11)C=CC1=O QEYYTDYNANSOII-GWOJJWRWSA-N 0.000 description 1
- JEBFEEVAYBWHLU-AXQFOSQISA-N OC(C1NC1(C1)Cc2ccc3O)(C11c2c3O[C@H]11)C=CC1=O Chemical compound OC(C1NC1(C1)Cc2ccc3O)(C11c2c3O[C@H]11)C=CC1=O JEBFEEVAYBWHLU-AXQFOSQISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a process for the purification of noroxymorphone compounds.
- the present invention also relates to a process for the preparation of pure noroxymorphone compounds, in particular naltrexone and naloxone, in particular of pure naltrexone.
- Noroxymorphone is referred to chemically as 7, 8-dihydro-14-hydroxy-normorphinone or as ⁇ , ⁇ -dihydro-14-hydroxy-normorphinone and corresponds to the formula
- Noroxymorphone compounds and their preparation are described for example in DE 272 78 05.
- a selected derivative of noroxymorphone is the compound known as naltrexone, which has the following chemical formula:
- Naltrexone and its derivatives and salts for example naltrexone hydrochloride, N-methylnaltrexone bromide (methylnaltrexone) or naltrexone methobromide, are known pharmaceutically active compounds which are used, in particular, for reducing the psychological dependence on drug abuse.
- naltrexone methobromide is used as antagonist nist of the MU receptor used to prevent side effects of narcotic drugs.
- Naloxone (CAS No. 465-65-5) is substituted on the nitrogen atom by an allyl residue and is similarly pharmaceutically effective.
- morphine derivatives these compounds are synthesized from precursors derived from the class of morphine-like alkaloids of the poppy.
- potential precursors of these compounds such as, for example, corresponding ⁇ -substituted and / or ⁇ -substituted alcohols, may be present as impurities in the plant extraction mixture, which in turn may contain ⁇ , ⁇ -unsaturated compounds such as, for example, the compound of formulas (Ia), (Ib ) and (Ic).
- ⁇ , ⁇ -unsaturated toxic compounds may be produced in the preparation of naltrexone starting from said plant extracts, such compounds being mutagenic, teratogenic and / or or carcinogenic.
- step (a) and of step (b), including possible isolation of the reaction products is preferably carried out in a non-aqueous medium, preferably also in a non-alcoholic medium. Preference is given to the removal of the leaving groups before the hydrogenation.
- the hydrogenation, d. i. Step (c), in the presence of non-protic and mild conditions, may also be carried out in the presence of protic solvents such as water and alcohols. After the hydrogenation additionally any remaining leaving groups can be removed by hydrolysis.
- the starting mixture or any intermediate or the final product d. i. Naltrexone or naloxone, preferably the starting mixture or an intermediate, subjected to the inventive treatment according to step (a) and step (b) and then hydrogenated.
- the starting mixture usually consists of oxymorphone,
- the present invention relates to a process for purifying plant extracts which consist essentially of noroxymorphone compounds of the formula (II) and which contain, as impurities in ⁇ , ⁇ -position, unsaturated noroxymorphone compounds and further contaminating noroxymorphone compounds:
- Ri hydrogen, optionally substituted by phenyl or chlorine (Ci-C 8 ) alkyl, (C 2 -C 4 ) alkenyl or a known leaving group leaving, means, characterized in that (a) the plant extract, or reacting the product of a subsequent stage in the synthesis of a selected noroxymorphone compound in a reaction whereby the hydroxyl groups present in the mixture are converted into leaving groups of the formula -OR 2 , where R 2 is the introduced residue of the leaving group, (b) optionally again removes these leaving groups and then (c) subjecting the resulting mixture to a selective hydrogenation, so that a saturated bond is formed in the ⁇ , ⁇ -position of the contaminating noroxymorphone compounds and the other optionally present abatement each are converted into a hydroxyl group and then optionally isolated (d) the pure noroxymorphone compound.
- the present invention also relates to the oxymorphone compounds of the formula (II) purified by the process according to the invention or a mixture of such compounds and to pharmaceutical formulations containing such a compound.
- R 1 is preferably hydrogen, (C 1 -C 8 ) -alkyl, (C 2 -C 4 ) -alkenyl or a leaving group; preferably (C 1 -C 6 ) -alkyl, allyl or hydrogen, preferably (C 1 -C 6 ) -alkyl or hydrogen.
- R 1 as leaving group is preferably (C 1 -C 4 ) -alkyloxycarbonyl [(C 1 -C 8 ) -alkyl-OC (0) -] or phenyloxycarbonyl [phenyl-O-C (O) -], preferably ethyloxycarbonyl, isobutyloxycarbonyl , or tert.
- Butyloxycarbonyl (Boc) cyclohexyloxycarbonyl, preferably ethyloxycarbonyl or tert. Butyloxycarbonyl (Boc).
- the introduction of the radical is carried out in a manner known per se by reacting the compound of general formula (II) (in which R 1 is hydrogen or a displaceable radical), for example with Boc anhydride (Boc-0-Boc) ⁇ [( CH 3) 3 COC (O)] 2 -0 ⁇ or Boc-carbamate [(CH 3) 3 COC (0) -N (CI_ 4 alkyl) 2], are reacted.
- Boc anhydride Boc-0-Boc
- Boc-carbamate [(CH 3) 3 COC (0) -N (CI_ 4 alkyl) 2
- a compound or a mixture of compounds is hydrogenated, wherein R 1 is neither methylene-cyclopropyl nor allyl and one prepares from the hydrogenated product, the preferred end product.
- -OR 2 may also form a carbonic acid ester moiety wherein R 2 represents (C 1 -C 8 ) alkyloxycarbonyl or phenyloxycarbonyl; preferably ethyloxycarbonyl, isobutyloxycarbonyl, or tert. Butyloxycarbonyl (Boc), cyclohexyloxycarbonyl, preferably ethyloxycarbonyl or tert. Butyloxycarbonyl (Boc).
- acid chlorides or acid anhydrides for example acetic anhydride, acetyl chloride, trifluoroacetic anhydride, methanesulfonyl chloride, methanesulfonyl anhydride, toluenesulfonyl chloride, and related compounds known per se.
- R 1 is an alkyl group
- the further reaction of the reaction mixture obtained in step (a) is carried out in anhydrous medium, preferably also in alcohol-free medium, as can be formed by the presence of water impurities, especially alcohols in ⁇ - or ß-position by the addition of water and optionally alcohol at ⁇ , ⁇ -position unsaturated compounds.
- anhydrous medium preferably also in alcohol-free medium
- the hydrogenation according to step (c) can be carried out under mild conditions in aqueous and / or alcoholic solvents. For such treatments in anhydrous and preferably alcohol-free media in particular non-protic solvents such.
- B. tert. Butyl ether suitable.
- step (a) is by treating the reaction mixture, optionally with heating, with a Acylating agent, as previously described introduced.
- a Acylating agent as previously described introduced.
- organic solvents for. B. MTBE (methyl ether-butyl ether), the product is precipitated.
- the removal of the leaving groups according to step (b) is preferably carried out by heating the reaction product from step (a) in non-aqueous solvents, optionally for several hours, preferably in non-protic solvents such as THF, dioxane, ethyl acetate , MTBE, DMF, DMSO and the like, optionally with the addition of a base such as potassium tert. butoxide or lithium hydroxide in non-protic solvents such as THF, dioxane, or ethyl acetate.
- a base such as potassium tert. butoxide or lithium hydroxide
- the product is subsequently precipitated by addition of a non-protic solvent.
- Hydrogenation conditions are known per se and z. B. in EP 0 158 476, WO99 / 02529, WO 95/32973 or 0 91/05768. According to the invention, preference is given to hydrogenation conditions in which, for the hydrogenation in step (c), elementary hydrogen and / or conditions or. Compounds which generate elementary hydrogen in situ can be used.
- step (c) elemental hydrogen, cyclohexene and / or cyclohexadiene (which react with hydrogen to give benzene) and / or oniummmoniumformiat (which decomposes with hydrogen to carbon dioxide and ammonia ) are used as hydrogen sources or in a solvent from the class of polar organic solvents, optionally with the addition of water for solubilization, such as hydrogenation catalysts.
- hydrogenation catalysts are described hereinbelow.
- Transfer hydrogenations can generally be carried out under normal pressure and are known per se. Particularly preferred is the catalytic hydrogenation using noble metal catalysts in heterogeneous or homogeneous form.
- Such Edelmetallkatalysatoren- are preferably selected from compounds of the group of transition metals of the Periodic Table of the Elements, in particular selected from metals of VIII.
- Group of the Periodic Table their compounds and complexes, in particular of ruthenium (Ru) and osmium (Os), cobalt (Co), rhodium (Rh), and iridium (Ir), nickel (Ni), palladium (Pd) and platinum (Pt ).
- ruthenium (Ru) and osmium (Os) cobalt (Co), rhodium (Rh), and iridium (Ir), nickel (Ni), palladium (Pd) and platinum (Pt ).
- ruthenium (Ru) and osmium (Os) cobalt (Co), rhodium (Rh), and iridium (Ir), nickel (Ni), palladium (Pd) and platinum (Pt ).
- palladium compounds are known per se Pd (0) compounds such as tetrakis (triphenylphosphine) - palladium and the corresponding complexes with the ligands tri (2-tolyl) phosphine, tri (2-furyl) phosphines, tri (tert. - butyl) phosphine, resp.
- Pd (0) compounds such as tetrakis (triphenylphosphine) - palladium and the corresponding complexes with the ligands tri (2-tolyl) phosphine, tri (2-furyl) phosphines, tri (tert. - butyl) phosphine, resp.
- the catalysts are used in catalytic amounts, preferably in amounts of 0.0005-0.01% by weight of noble metal, preferably about 0.001 - 0.005% by weight of precious metal, calculated on the weight of the crude product used.
- the specified upper limit is not critical. Thus, higher amounts of catalyst, for. B. ' equimolar amounts based on the crude product used. As a rule, this is not necessary.
- the hydrogenation is preferably carried out with hydrogen gas, preferably in an inert solvent, such as in organic acids, such as preferably glacial acetic acid, formic acid, propionic acid or a mixture of these compounds; in alcohols, such as preferably methanol, ethanol, isopropyl alcohol, n-butanol or a mixture of these compounds; in nitriles, preferably acetonitrile and / or propionitrile; in ketones, preferably acetone and / or 2-butanone; in esters such as ethyl acetate, in polar aprotic solvents such as preferably dimethylformamide (DMF) or dimethylsulfonamide (DMSO), optionally with the addition of water.
- an inert solvent such as in organic acids, such as preferably glacial acetic acid, formic acid, propionic acid or a mixture of these compounds; in alcohols, such as preferably methanol, ethanol, isopropyl alcohol, n-but
- protic solvents in particular methanol, ethanol, isopropyl alcohol, n-butanol, or aprotic polar solvents, preferably acetone, DMF, acetonitrile, optionally mixed with 1-99 wt. % Water and preferably in the presence of an organic acid such as, for example, acetic acid, trifluoroacetic acid, propionic acid, formic acid, preferably acetic acid, preferably in a concentration of 0.1% by weight to 99% by weight.
- an organic acid such as, for example, acetic acid, trifluoroacetic acid, propionic acid, formic acid, preferably acetic acid, preferably in a concentration of 0.1% by weight to 99% by weight.
- the hydrogenation is preferably conducted at a temperature ranging from 0 ° C to 150 0 C, preferably in the range of 20 0 C to 100 0 C, preferably in the range from normal pressure to 100 bar, preferably in the range from normal pressure to 10 bar is performed.
- the present invention also relates to a process for the preparation of pure noroxymorphone from plant extracts which consist essentially of noroxymorphone and which contain contaminating noroxymorphone compounds, characterized in that oxymorphone of the aforementioned formula (II), wherein R 1 is methyl, as a plant extract and (a) reacting the plant extract in a reaction which converts the hydroxyl groups present in the mixture into leaving groups of the formula -OR 2 wherein R 2 represents the introduced residue of a leaving group such as those previously described for Ri, preferably acyl , preferably acetyl;
- R 3 is a leaving group, as described above for R 1 , preferably alkyl oxycarbonyl, preferably ethyloxycarbonyl or Boc, preferably ethyloxycarbonyl;
- step (b) at least one of the products obtained in steps (a), (a1) and / or (a2), preferably one of the products obtained in steps (a1) or (a2), preferably in stage (a2) subjecting to selective hydrogenation reaction, as described above, and
- the product obtained in step (a2) can also be further processed, preferably into naltrexone or naloxone or a salt of these compounds or a quaternary derivative of these compounds, preferably the hydrochloride, hydrobromide, methochloride or methobromide, preferably to the corresponding salts or quaternary derivatives of naltrexone.
- the selective hydrogenation also removes the leaving groups, but these may optionally be carried out separately in step (a2) and / or to completion, if necessary, following the hydrogenation.
- MTBE methyl tert. butyl ether
- step (a1) preference is given to reacting by means of ethyl chloroformate in an aprotic solvent, preferably acetonitrile, under basic conditions, such as K 2 CO 3 , to isolate an oxymorphone compound in which R 3 is ethoxycarbonyl or the compound obtained the corresponding diacetyloxymorphone ethoxycarbamate.
- an aprotic solvent preferably acetonitrile
- step (a2) the leaving groups R 2 and R 3 are removed from the reaction product obtained from steps (a) and (a1).
- the reaction product from stage (a) or (a1) is heated in non-aqueous solvents, preferably in non-protic solvents such as THF, dioxane, ethyl acetate, MTBE, DMF, DMSO and the like, optionally over several hours. optionally with the addition of a base such as potassium tert. Butylate or lithium hydroxide, in non-protic solvents such as THF, dioxane, ethyl acetate.
- the product is subsequently precipitated by addition of a non-protic solvent.
- step (b) the isolated product, e.g. B. Diacetyloxymorphone ethoxycarbamate, preferably dissolved in glacial acetic acid and subjected to hydrogenation by introducing hydrogen gas under the conditions given above, catalyzed by palladium on activated carbon. Subsequently, the remaining leaving groups R 4 and R 5 by addition of 40% sulfuric acid cleaved to the reaction mixture, with Noroxymorphon- SuIfat forms, which can be optionally isolated. By adding base, for example by adding ammonia solution in ethanol / water, the reaction mixture can be neutralized and worked up, whereby the free noroxymorphone can be isolated.
- base for example by adding ammonia solution in ethanol / water
- the free noroxymorphone is insoluble in a water / ethanol mixture at a weakly alkaline acid value (pH), preferably pH 8-10, and precipitates at the pH adjustment as a crystalline solid, whereby it can be filtered off.
- a weakly alkaline acid value pH 8-10
- the noroxymorphone thus obtained can thus be further processed, preferably to give high-purity naltrexone or naloxone (CAS No. 465-65-5) or to salts or quaternary derivatives.
- the hydrochlorides and hydrobromides are preferred.
- naltrexone methobromide also referred to as methylnaltrexone
- naloxone methobromide also referred to as methylnaloxone (CAS No. 73232-50-5)
- the noroxymorphone prepared according to the invention can, for. B. to high purity naltrexone or high purity naloxone, or to a high purity salt or quaternary derivative of these compounds.
- the present invention relates to a process for the preparation of highly pure salts and quaternary derivatives of naltrexone and naloxone, in which the critical olefinic impurities are below the detection limit, preferably salts of naltrexone, by reacting the starting product noroxymorphone with the corresponding alkylating agent, d. i. with cyclopropylmethyl bromide (for naltrexone) or with allyl bromide (for naloxone) and the product naltrexone or naloxone either with an acid, preferably with diluted hydrochloric acid or hydrogen bromide to the corresponding salt, in the case described to the hydrochloride or.
- the critical olefinic impurities are below the detection limit, preferably salts of naltrexone
- Hydrobromide or treated with a further alkylating agent, preferably with methyl bromide, to obtain naltrexone methobromide or naloxone methobromide; characterized in that at least the starting material or an intermediate product of steps (a) or (b) or the end product, preferably an intermediate product of steps (a) or (b), preferably step (b) of Hydrogenation reaction subjects, as described above.
- a further alkylating agent preferably with methyl bromide
- Example 4 [Reaction of 3,4-diacetyloxymorphone (DAOM) containing trace 3, 8, 14-triacetyloxymorphone to give 3, 8, 14-triacetyloxymorphone-free 3,14-diacetyloxymorphone (DAOM); Elimination of the leaving group] 20 g of diacetyloxymorphone with traces of 3, 8, 14-triacetyloxymorphone are tert in a mixture of 20 g. Butyl methyl ether and 3-5 g of acetic acid were suspended at room temperature. The reaction solution is heated at 70 ° C. for 10-15 hours. It is then cooled and 70 g tert. Butyl methyl ether added.
- DAOM 3,4-diacetyloxymorphone
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006800045237A CN101115757B (zh) | 2005-02-11 | 2006-02-09 | 用于提纯降羟吗啡酮化合物的方法 |
US11/815,784 US8227609B2 (en) | 2005-02-11 | 2006-02-09 | Process for purifying noroxymorphone compounds |
CA2597350A CA2597350C (en) | 2005-02-11 | 2006-02-09 | Process for purifying noroxymorphone compounds |
DK06704529T DK1851226T3 (da) | 2005-02-11 | 2006-02-09 | Fremgangsmåde til oprensning af noroxymorphonforbindelser |
JP2007554413A JP5587541B2 (ja) | 2005-02-11 | 2006-02-09 | ノルオキシモルホン化合物の精製方法 |
ES06704529.4T ES2529045T3 (es) | 2005-02-11 | 2006-02-09 | Procedimiento para la purificación de compuestos de noroximorfona |
EP06704529.4A EP1851226B1 (de) | 2005-02-11 | 2006-02-09 | Verfahren zur reinigung von noroxymorphon-verbindungen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CHPCT/CH05/000076 | 2005-02-11 | ||
PCT/CH2005/000076 WO2006084389A1 (de) | 2005-02-11 | 2005-02-11 | Verfahren zur reinigung von noroxymorphon-verbindungen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006084412A1 true WO2006084412A1 (de) | 2006-08-17 |
WO2006084412A9 WO2006084412A9 (de) | 2007-09-20 |
Family
ID=35044741
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH2005/000076 WO2006084389A1 (de) | 2005-02-11 | 2005-02-11 | Verfahren zur reinigung von noroxymorphon-verbindungen |
PCT/CH2006/000087 WO2006084412A1 (de) | 2005-02-11 | 2006-02-09 | Verfahren zur reinigung von noroxymorphon-verbindungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH2005/000076 WO2006084389A1 (de) | 2005-02-11 | 2005-02-11 | Verfahren zur reinigung von noroxymorphon-verbindungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US8227609B2 (de) |
EP (1) | EP1851226B1 (de) |
JP (1) | JP5587541B2 (de) |
CN (1) | CN101115757B (de) |
CA (1) | CA2597350C (de) |
DK (1) | DK1851226T3 (de) |
ES (1) | ES2529045T3 (de) |
RU (1) | RU2401270C2 (de) |
WO (2) | WO2006084389A1 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010524938A (ja) * | 2007-04-16 | 2010-07-22 | マリンクロッド・インコーポレイテッド | 触媒性水素転移反応を使用する新規なオピエート還元 |
JP2011503040A (ja) * | 2007-11-09 | 2011-01-27 | サノフイ−アベンテイス | モルヒネ化合物の調製方法 |
JP2011506604A (ja) * | 2007-12-17 | 2011-03-03 | マリンクロッド・インコーポレイテッド | ノルモルフィナン塩を調製するためのプロセス |
US8871779B2 (en) | 2006-03-02 | 2014-10-28 | Mallinckrodt Llc | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
EP3252055A1 (de) | 2016-05-31 | 2017-12-06 | Alcaliber Investigacion Desarrollo e Innovacion, S.L. | Verfahren zur gewinnung von 3,14-diacetyloxymorphon aus oripavin |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007297827B2 (en) * | 2006-09-20 | 2012-09-20 | Mallinckrodt Llc | Preparation of substituted morphinan-6-ones and salts and intermediates thereof |
CA2674915C (en) | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
EP2073636B1 (de) * | 2006-10-17 | 2012-09-05 | Penick Corporation | Verfahren für die herstellung von oxymorphon |
WO2008070658A1 (en) | 2006-12-04 | 2008-06-12 | Noramco, Inc. | Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone |
CN104761561A (zh) | 2006-12-04 | 2015-07-08 | 诺拉姆科有限公司 | 减少羟考酮碱中杂质的方法 |
GB0624880D0 (en) * | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
EP2137189B1 (de) * | 2007-03-06 | 2015-05-06 | Mallinckrodt LLC | Verfahren zur herstellung quaternärer n-alkyl-morphinin-alkaloid-derivate |
US9040726B2 (en) * | 2007-03-06 | 2015-05-26 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
US8158793B2 (en) | 2007-11-26 | 2012-04-17 | Siegfried Ltd. | Demethylation of 14-hydroxy substituted alkaloid derivatives |
EP2062896A1 (de) * | 2007-11-26 | 2009-05-27 | Siegfried Ltd. | Demethylierung von 14-hydroxysubstituierten Alkaloidderivaten |
EP2244766A1 (de) * | 2007-12-07 | 2010-11-03 | Mallinckrodt Inc. | Befestigungssystem für eine angetriebene injektionsspritze |
WO2009122436A2 (en) * | 2008-03-31 | 2009-10-08 | Sun Pharmaceutical Industries Ltd. | An improved process for the preparation of morphinane analogues |
ES2641887T3 (es) * | 2008-05-27 | 2017-11-14 | Mallinckrodt Llc | Procesos y compuestos para la preparación de normorfinanos |
AU2014200890B2 (en) * | 2008-05-27 | 2016-02-04 | SpecGx LLC | Processes and compounds for the preparation of normorphinans |
EP2331508B1 (de) * | 2008-09-03 | 2014-11-12 | Mallinckrodt LLC | Substituierte berbine und verfahren zu ihrer synthese |
EP2580218B1 (de) | 2010-06-11 | 2015-02-25 | Rhodes Technologies | Verfahren zur n-dealkylierung von tertiären aminen |
AU2011263417B2 (en) | 2010-06-11 | 2014-03-27 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof |
EP2420503A1 (de) * | 2010-07-27 | 2012-02-22 | Universität Innsbruck | Verfahren zur Herstellung von 14-oxy-substituierten morphinan-6-onen |
CN102351869B (zh) * | 2011-10-24 | 2013-11-13 | 江苏奥赛康药业股份有限公司 | 一种溴化甲基纳曲酮的制备方法 |
GB201313915D0 (en) * | 2013-08-02 | 2013-09-18 | Johnson Matthey Plc | Process |
ES2784690T3 (es) | 2013-12-05 | 2020-09-29 | Univ Bath | Nuevos compuestos opioides y sus usos |
CN103626782B (zh) * | 2013-12-13 | 2016-07-13 | 山东新华制药股份有限公司 | 溴甲纳曲酮的制备方法 |
EP3166948A1 (de) * | 2014-07-09 | 2017-05-17 | Rhodes Technologies Inc. | Reduktion der anteile von alpha-, beta-ungesättigten ketonen in morphinanderivatzusammensetzungen |
CN105753874A (zh) * | 2014-12-15 | 2016-07-13 | 北大方正集团有限公司 | 一种Delta-7甲基纳曲酮甲酸盐及其制备方法 |
CN105753875A (zh) * | 2014-12-15 | 2016-07-13 | 北大方正集团有限公司 | 一种乙酰化Delta-7甲基纳曲酮甲酸盐及其制备方法 |
CN105753876A (zh) * | 2014-12-15 | 2016-07-13 | 北大方正集团有限公司 | 一种Delta-7溴甲纳曲酮的制备方法 |
WO2022094470A1 (en) | 2020-11-02 | 2022-05-05 | Rhodes Technologies | Process for purifying noroxymorphone |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0158476A1 (de) * | 1984-03-27 | 1985-10-16 | Mallinckrodt, Inc. (a Delaware corporation) | Herstellung von Noroxymorphon aus Morphin |
WO1991005768A1 (en) * | 1989-10-16 | 1991-05-02 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Total synthesis of northebaine, normorphine, noroxymorphone enantiomers and derivatives via n-nor intermediates |
WO1995032973A1 (en) * | 1994-05-31 | 1995-12-07 | Mallinckrodt Chemical, Inc. | The preparation of nalbuphine having low levels of beta-epimer |
WO1999002529A1 (en) * | 1997-07-11 | 1999-01-21 | Penick Corporation | Preparation of oxymorphone, oxycodone and derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2727805A1 (de) | 1977-06-21 | 1979-01-04 | Goedecke Ag | Verfahren zur herstellung von oxynormorphon |
-
2005
- 2005-02-11 WO PCT/CH2005/000076 patent/WO2006084389A1/de not_active Application Discontinuation
-
2006
- 2006-02-09 WO PCT/CH2006/000087 patent/WO2006084412A1/de active Application Filing
- 2006-02-09 CA CA2597350A patent/CA2597350C/en active Active
- 2006-02-09 EP EP06704529.4A patent/EP1851226B1/de active Active
- 2006-02-09 US US11/815,784 patent/US8227609B2/en active Active
- 2006-02-09 JP JP2007554413A patent/JP5587541B2/ja active Active
- 2006-02-09 ES ES06704529.4T patent/ES2529045T3/es active Active
- 2006-02-09 DK DK06704529T patent/DK1851226T3/da active
- 2006-02-09 RU RU2007133670/04A patent/RU2401270C2/ru not_active IP Right Cessation
- 2006-02-09 CN CN2006800045237A patent/CN101115757B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0158476A1 (de) * | 1984-03-27 | 1985-10-16 | Mallinckrodt, Inc. (a Delaware corporation) | Herstellung von Noroxymorphon aus Morphin |
WO1991005768A1 (en) * | 1989-10-16 | 1991-05-02 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Total synthesis of northebaine, normorphine, noroxymorphone enantiomers and derivatives via n-nor intermediates |
WO1995032973A1 (en) * | 1994-05-31 | 1995-12-07 | Mallinckrodt Chemical, Inc. | The preparation of nalbuphine having low levels of beta-epimer |
WO1999002529A1 (en) * | 1997-07-11 | 1999-01-21 | Penick Corporation | Preparation of oxymorphone, oxycodone and derivatives |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871779B2 (en) | 2006-03-02 | 2014-10-28 | Mallinckrodt Llc | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
JP2010524938A (ja) * | 2007-04-16 | 2010-07-22 | マリンクロッド・インコーポレイテッド | 触媒性水素転移反応を使用する新規なオピエート還元 |
JP2011503040A (ja) * | 2007-11-09 | 2011-01-27 | サノフイ−アベンテイス | モルヒネ化合物の調製方法 |
US8455509B2 (en) | 2007-11-09 | 2013-06-04 | Sanofi | Method for the preparation of morphine compounds |
JP2011506604A (ja) * | 2007-12-17 | 2011-03-03 | マリンクロッド・インコーポレイテッド | ノルモルフィナン塩を調製するためのプロセス |
EP3252055A1 (de) | 2016-05-31 | 2017-12-06 | Alcaliber Investigacion Desarrollo e Innovacion, S.L. | Verfahren zur gewinnung von 3,14-diacetyloxymorphon aus oripavin |
WO2017207519A1 (en) | 2016-05-31 | 2017-12-07 | Alcaliber Investigación Desarrollo E Innovación, S.L. | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
Also Published As
Publication number | Publication date |
---|---|
US8227609B2 (en) | 2012-07-24 |
US20090270624A1 (en) | 2009-10-29 |
ES2529045T3 (es) | 2015-02-16 |
CA2597350C (en) | 2014-04-29 |
EP1851226A1 (de) | 2007-11-07 |
WO2006084389A1 (de) | 2006-08-17 |
DK1851226T3 (da) | 2015-03-02 |
WO2006084412A9 (de) | 2007-09-20 |
RU2401270C2 (ru) | 2010-10-10 |
RU2007133670A (ru) | 2009-03-20 |
CA2597350A1 (en) | 2006-08-17 |
JP2008530036A (ja) | 2008-08-07 |
CN101115757A (zh) | 2008-01-30 |
CN101115757B (zh) | 2010-12-22 |
JP5587541B2 (ja) | 2014-09-10 |
EP1851226B1 (de) | 2014-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1851226B1 (de) | Verfahren zur reinigung von noroxymorphon-verbindungen | |
EP2649040B1 (de) | Verfahren zur homogen-katalysierten, hochselektiven direkten aminierung von primären alkoholen mit ammoniak zu primären aminen bei hohem volumenverhältnis von flüssig- zu gasphase und/oder hohen drücken | |
DE2346535B2 (de) | Verfahren zur Herstellung von 7-Dimethylamino-e-desmethyl-e-desoxytetracyclin über 9-tert.Butyl-6-desmethyl-6-desoxytetracyclin | |
HUE034668T2 (hu) | Eljárás morfinán-származékok szintézisére és azok intermedierjei | |
SK286047B6 (sk) | Spôsob prípravy derivátov 4,5alfa-epoxy-6-oxomorfínanu | |
DE2413102C3 (de) | Verfahren zur Herstellung von l-(3,5-Dihydroxyphenyl)-t-hydroxy-2- eckige Klammer auf 1-methyl-2-(4-hydroxyphenyl)- äthyl] -aminoäthan | |
JP5270091B2 (ja) | 7−アルキル−10−ヒドロキシ−20(s)−カンプトテシンを調製するためのプロセス | |
FI85010B (fi) | Foerfarande foer framstaellning av rimantadin. | |
DE602005004834T2 (de) | Ein verbessertes Verfahren für die Synthese von Methylphenidaten und Zwischenprodukten | |
DE60032453T2 (de) | Ein verfahren zur synthese von ritonavir | |
CH632769A5 (de) | Verfahren zur herstellung von anthracyclinen. | |
DE2409675A1 (de) | Alpha-alkyl(oder -aryl)-thio-5-hydroxytryptophan-derivat und verfahren zu seiner herstellung | |
EP2812317B1 (de) | Verfahren zur stereoselektiven synthese von 1,4-geschützten 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5]undecane | |
DE2308227A1 (de) | Verfahren zur herstellung von alpha6-deoxytetracyclinen | |
DE1643767C3 (de) | Verfahren zur Herstellung von in 7-Stellung substituierten Tetracyclinen und Zwischenprodukte hierfür | |
CH653023A5 (de) | Verfahren zur herstellung von 2-alkyl-4-amino-5-aminomethylpyrimidinen. | |
DE3200809A1 (de) | Anthracyclin-glycoside, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
DE60127805T2 (de) | Verfahren zur Herstellung von optisch aktiven 3-Aminopyrrolidin-2,5-dion-derivaten und optisch aktiven 3-Aminopyrrolidin-derivaten | |
EP0729971A1 (de) | Verfahren zur Herstellung von Ivermectin | |
DE3520469A1 (de) | Neue anthracycline, verfahren zu deren herstellung, zwischenverbindungen und pharmazeutische zubereitung | |
EP0277620B1 (de) | Verfahren zur Herstellung von optisch aktivem beta-Methylcholin | |
JPH0791252B2 (ja) | 7‐ジメチルアミノ‐6‐デメチル‐6‐デオキシテトラサイクリンの製造法 | |
DE3011156A1 (de) | Verfahren zur herstellung von isochinolinderivaten | |
EP0205031A1 (de) | Verfahren zur Herstellung von 4-Benzyl-aspartat | |
CH616680A5 (en) | Process for the preparation of a substituted benzopyrano[3,4-c]pyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006704529 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2597350 Country of ref document: CA Ref document number: 2007554413 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680004523.7 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007133670 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006704529 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11815784 Country of ref document: US |